- Home
- SRM vs DWTX Comparison
SRM vs DWTX Comparison
Compare SRM & DWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRM
- DWTX
- Stock Information
- Founded
- SRM 1979
- DWTX 2012
- Country
- SRM United States
- DWTX United States
- Employees
- SRM N/A
- DWTX N/A
- Industry
- SRM
- DWTX
- Sector
- SRM
- DWTX
- Exchange
- SRM Nasdaq
- DWTX NYSE
- Market Cap
- SRM 9.0M
- DWTX 9.2M
- IPO Year
- SRM 2023
- DWTX N/A
- Fundamental
- Price
- SRM $7.93
- DWTX $4.85
- Analyst Decision
- SRM
- DWTX Strong Buy
- Analyst Count
- SRM 0
- DWTX 1
- Target Price
- SRM N/A
- DWTX $10.00
- AVG Volume (30 Days)
- SRM 20.8M
- DWTX 33.5K
- Earning Date
- SRM 08-11-2025
- DWTX 08-14-2025
- Dividend Yield
- SRM N/A
- DWTX N/A
- EPS Growth
- SRM N/A
- DWTX N/A
- EPS
- SRM N/A
- DWTX N/A
- Revenue
- SRM $4,394,659.00
- DWTX N/A
- Revenue This Year
- SRM N/A
- DWTX N/A
- Revenue Next Year
- SRM N/A
- DWTX N/A
- P/E Ratio
- SRM N/A
- DWTX N/A
- Revenue Growth
- SRM N/A
- DWTX N/A
- 52 Week Low
- SRM $0.26
- DWTX $1.62
- 52 Week High
- SRM $12.80
- DWTX $29.28
- Technical
- Relative Strength Index (RSI)
- SRM 61.58
- DWTX N/A
- Support Level
- SRM $6.42
- DWTX N/A
- Resistance Level
- SRM $8.85
- DWTX N/A
- Average True Range (ATR)
- SRM 2.02
- DWTX 0.00
- MACD
- SRM -0.11
- DWTX 0.00
- Stochastic Oscillator
- SRM 54.11
- DWTX 0.00
About SRM SRM Entertainment Inc.
SRM Entertainment Inc is a trusted toy and souvenir designer and developer, selling into theme parks and entertainment venues. It has developed, manufactured, and supplied the entertainment and amusement park industry with exclusive products that are often only available to consumers inside SRM's customer base venues such as Walt Disney Parks and Resorts, Universal Studios, SeaWorld, Six Flags, Great Wolf Lodge, Dollywood, and Merlin Entertainment. Its product category includes The Smurfs and Zoonicorns, Sammy Sloth, lilita Llama, kyle Koala, and Hanna Hedgehog.
About DWTX DOGWOOD THERAPEUTICS INC
Dogwood Therapeutics Inc, formerly Virios Therapeutics Inc, is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a virus-triggered abnormal immune response, such as fibromyalgia (FM) and long COVID (LC). Its product candidates include IMC-1 and IMC-2. IMC-1 is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.